Neuromodulation (VNS, RNS, DBS)
Neuromodulation (VNS, RNS, DBS)
What Do You Need to Know?
- Three FDA-approved neuromodulation devices for drug-resistant epilepsy: VNS (1997), RNS (2013), and anterior thalamic DBS (2018)
- VNS: Open-loop peripheral nerve stimulation; simplest and most established; ~50% seizure reduction at 1 year; seizure freedom only 2–8%
- RNS: Closed-loop intracranial stimulation at seizure focus; highest long-term efficacy (≥70% median reduction at 5–9 years, Nair 2020 peer-reviewed; ~82% at 3 years reported in the Post-Approval Study, industry-sponsored real-world data); unique diagnostic value via chronic ECoG
- DBS (ANT): Open-loop bilateral anterior thalamic stimulation; modulates circuit of Papez; 69% reduction at 5 years; depression (15%) is a notable side effect
- Key distinction: VNS = broadest indication, no intracranial surgery; RNS = best for identifiable foci / eloquent cortex / bilateral MTLE; DBS = best for diffuse/multifocal onset
- All three: Efficacy improves over months to years; reversible; MRI-conditional; do not preclude future resective surgery
🚩 Don’t Miss — Test-Day Priorities
- VNS targets LEFT cervical vagus: Right vagus innervates SA node → bradyarrhythmia/asystole risk; bilateral or right-sided VNS is CONTRAINDICATED
- VNS “50/50 rule”: ~50% of patients achieve ≥50% seizure reduction by 1–2 yr; seizure freedom only 2–8% — palliative, not curative
- VNS AutoStim: Detects ictal tachycardia (occurs in 80–90% of seizures) → closed-loop bonus stimulation; threshold set 20–40% above resting HR
- Hoarseness is the most common VNS side effect (~62%, ON-phase only); screen for OSA aggravation before implant
- RNS = closed-loop intracranial stimulator (NeuroPace, FDA 2013); indicated for ≤2 epileptogenic foci that are unresectable (bilateral mesial temporal, eloquent cortex)
- RNS efficacy accumulates over years: ~75% median seizure reduction at 9 yr; also provides chronic ambulatory ECoG for surveillance/diagnosis
- DBS (ANT): Bilateral anterior thalamic nucleus stimulation (SANTE trial, FDA 2018); modulates circuit of Papez; ~69% reduction at 5 yr; depression in ~15%
- Centromedian thalamic DBS: Investigational target for generalized epilepsy syndromes (LGS, generalized tonic-clonic) — not ANT
- Device choice: VNS = broad “all-comers” with no resectable focus; RNS = identifiable focal/multifocal/eloquent; DBS = diffuse or multifocal onset
- All three are MRI-conditional (model-specific), reversible, and do NOT preclude future resective surgery; SUDEP risk reduced with VNS (observational only)
🔍 Buzzwords & Pathognomonic FindingsMechanism / target · Indications / outcomes · Complications / monitoring
Mechanism / target
- Left cervical vagus nerve (CN X), ~80% afferent → VNS target (right vagus avoided — SA node)
- NTS → locus coeruleus → cortical norepinephrine → VNS antiseizure mechanism
- Closed-loop cortical/depth leads sensing seizure onset → RNS (NeuroPace) — skull-mounted neurostimulator
- Bilateral anterior thalamic nucleus (ANT), circuit of Papez → DBS for focal epilepsy (SANTE)
- Centromedian thalamic nucleus → DBS for generalized epilepsy / LGS (investigational)
- Open-loop vs closed-loop: VNS & DBS = open-loop; RNS = closed-loop responsive
Indications / outcomes
- FDA 1997, focal epilepsy ≥12 yr (now ≥4 yr since 2017) → VNS
- FDA 2013, ≤2 unresectable foci, bilateral MTLE, eloquent cortex → RNS
- FDA 2018, SANTE trial, adult drug-resistant focal epilepsy → ANT-DBS
- “50/50 rule” (~50% of patients, ~50% reduction at 1–2 yr) → VNS outcome
- ~75% median seizure reduction at 9 yr, chronic ECoG surveillance → RNS long-term
- ~69% reduction at 5 yr, duty cycle 1 min ON / 5 min OFF → ANT-DBS (SANTE)
- Magnet swipe during prodrome / aura → VNS on-demand extra stimulation
- Treatment-resistant depression (2005 approval) → VNS (secondary indication)
Complications / monitoring
- Hoarseness/voice change during ON phase (~62%, most common) → VNS
- Cough, dyspnea on stim, OSA aggravation, neck pain → VNS
- Bradycardia/asystole (intraoperative lead test, rare) → VNS (CONTRAINDICATED: right or bilateral vagus, prior bilateral vagotomy)
- Intracranial infection 4–5%, hemorrhage 1–2% → RNS / DBS
- Postoperative depression ~15%, memory complaints → ANT-DBS (avoid in unstable mood/psychosis/cognitive decline)
- Battery replacement every 6–10 yr; lead fracture 1–3% → VNS hardware
- MRI-conditional, model-specific (1.5T head transmit, body-coil restrictions) → all three devices
- Slow benefit (months for VNS, years for RNS/DBS); continue ASMs periprocedurally → patient counseling
Vagus Nerve Stimulation (VNS)
Mechanism of Action
- Target: Left cervical vagus nerve (CN X) — ~80% afferent fibers
- Left vagus chosen: Right vagus has predominant innervation of the SA node (sinoatrial), while the left vagus predominantly innervates the AV node; stimulating right vagus carries higher risk of bradyarrhythmia/sinus arrest
- Pathway: Vagal afferents → nucleus tractus solitarius (NTS) → widespread brainstem/cortical projections
- Noradrenergic: NTS → locus coeruleus → cortical norepinephrine release (antiseizure)
- GABAergic: Enhanced thalamic inhibitory tone via thalamic reticular nucleus
- Thalamocortical: Desynchronization of thalamocortical circuits → reduces seizure propagation
- Anti-inflammatory: Cholinergic anti-inflammatory pathway → reduces TNF-α, IL-6
FDA Approval & Indications
- FDA approved 1997 for drug-resistant focal/partial-onset seizures in patients ≥12 years; pediatric indication expanded to ≥4 years in 2017
- Also FDA-approved for treatment-resistant depression (2005)
- Off-label: generalized epilepsies, Lennox-Gastaut syndrome, Dravet syndrome
Efficacy
- 3 months: 36% median seizure reduction
- 1 year: 51% median seizure reduction
- 50% responder rate: ~50% achieve ≥50% reduction by 1–2 years
- Seizure freedom: Only 2–8% — VNS is palliative, not curative
- Progressive improvement: Efficacy increases over first 1–2 years
Standard Programming Parameters
| Parameter | Starting Value | Therapeutic Target |
|---|---|---|
| Output current | 0.25 mA | 1.5–2.0 mA (titrate by 0.25 mA q2–4 wk) |
| Frequency | 30 Hz | 30 Hz (20 Hz if side effects) |
| Pulse width | 250 μs | 250–500 μs |
| Duty cycle | 30 s ON / 5 min OFF | Rapid cycling: 21–30 s ON / 1.1–1.8 min OFF |
Autostimulation (Closed-Loop Feature)
- Newer generators (AspireSR, SenTiva) detect ictal tachycardia → extra stimulation burst
- Ictal tachycardia occurs in 80–90% of seizures, often preceding clinical onset by seconds
- Threshold set 20–40% above resting heart rate; operates alongside standard cycling
- Limitation: Exercise/anxiety can trigger false detections
Side Effects
- Hoarseness: Most common (62%) — during ON phase only; improves with acclimatization
- Cough, throat pain, dyspnea: Common during titration
- OSA aggravation: Laryngeal narrowing; screen at-risk patients with polysomnography
- Surgical: Infection 3–6%, vocal cord paralysis ~1%, lead fracture 1–3%
- Bradycardia/asystole: Rare, primarily during intraoperative lead testing; rare late events reported
VNS & SUDEP
- SUDEP in drug-resistant epilepsy: 6–9 per 1,000 patient-years
- VNS-treated patients: 2–4 per 1,000 patient-years (observational data)
- Proposed: improved autonomic regulation, enhanced postictal arousal
- Caution: observational data with selection bias; no RCT powered for SUDEP
Responsive Neurostimulation (RNS / NeuroPace)
Mechanism & Design
- Closed-loop: Continuously monitors intracranial ECoG via 2 leads (4 contacts each)
- Detects patient-specific seizure-onset patterns → delivers brief stimulation to abort seizure
- Neurostimulator embedded in skull-recessed ferrule (craniotomy)
- Dual mechanism: Acute seizure disruption + long-term neuromodulatory plasticity
FDA Approval & Indications
- FDA approved 2013 for adults (≥18 years) with drug-resistant focal epilepsy
- Requires 1–2 identifiable seizure foci
- Especially suited for: eloquent cortex onset, bilateral MTLE, prior failed resection
Efficacy
| Timepoint | Median Seizure Reduction | Key Result |
|---|---|---|
| Pivotal RCT — 3 mo | 38% vs. 17% sham | Statistically significant |
| Open-label — 2 yr | 53% | ~55% responder rate |
| Open-label — 6 yr | 66% | Progressive improvement |
| Post-Approval Study — 3 yr | 82% | 42% seizure-free ≥6 mo (Post-Approval Study; published 9-year Nair 2020 data showed 28% ≥6-mo seizure-free) |
| 9-year follow-up | ~75% | Cognition maintained or improved |
Diagnostic Value — Chronic Ambulatory ECoG
- Unique among all neuromodulation devices — continuous intracranial EEG under real-world conditions
- Objective seizure quantification (diaries undercount by ≥50%)
- Bilateral MTLE: Can identify dominant focus (≥90% from one side) → enables curative resection
- Reveals circadian and multidien seizure patterns; monitors medication response
- Diagnostic-therapeutic bridge: RNS first (treat + diagnose), then guided resection
- Bilateral hippocampal RNS: Geller et al. 2017 reported ~70% median reduction in mesial temporal lobe epilepsy at 6 years
Complications
- Infection: 3.7% at 3 months; up to 12% long-term
- Lead revision: 4.7%
- Intracranial hemorrhage: ~3% at implantation
- Battery replacement: Every 3–4 years (cranial procedure)
- Neuropsychological testing: no decline over 9 years; some improvement
Deep Brain Stimulation — Anterior Nucleus of Thalamus (ANT-DBS)
Mechanism
- Target: Bilateral anterior nuclei of thalamus (ANT)
- Circuit of Papez: Hippocampus → fornix → mammillary bodies → anterior thalamus → cingulate → hippocampus
- Open-loop scheduled cycling; desynchronizes thalamocortical circuits; raises seizure threshold
- FDA approved 2018 (US); 2010 in Europe; drug-resistant focal epilepsy in adults
SANTE Trial & Long-Term Data
| Timepoint | Median Seizure Reduction | Key Result |
|---|---|---|
| 3-mo blinded phase | 40% vs. 15% sham | Statistically significant |
| 2 years | 56% | 54% responder rate |
| 5 years | 69% | 18% experienced ≥6-month seizure-free intervals at some point during 5-year follow-up (SANTE; cumulative, not point-prevalence) |
| 10+ years | Stable or improved | Durable long-term safety |
MORE Registry (Real-World Data)
- 170 patients, 25 sites, 13 countries
- 2-year: 33% reduction (more modest than SANTE — real-world population)
- 5-year: 56% reduction; confirms long-term progressive improvement
Standard Programming
- Frequency: 145 Hz | Pulse width: 90 μs | Cycling: 1 min ON / 5 min OFF
- Voltage: 2–5 V, gradually increased; reduce at night to mitigate sleep disruption
Side Effects
- Depression: 15% at 5 years (cumulative ~37% by 7 years, Salanova 2021) — ANT stimulation of limbic circuitry; suicides have occurred in SANTE long-term follow-up (multiple cases reported in Salanova 2015 and 2021); psychiatric screening and monitoring required
- Memory symptoms: 13% at 5 years (cumulative ~27% long-term; subjective — formal testing often normal)
- Paresthesias: 18% (usually transient)
- Sleep disruption: Common — mitigated by night-time programming
- Infection: ~9% | Hemorrhage: ~5% at implantation (most asymptomatic)
Centromedian Nucleus DBS (CMN-DBS)
- Target: Centromedian nucleus — intralaminar thalamus with widespread cortical projections
- Logical target for generalized seizure networks (especially LGS)
- ESTEL trial: Double-blind, sham-controlled RCT in Lennox-Gastaut syndrome
- Significant reduction in tonic-clonic and tonic seizures vs. sham
- Not yet FDA-approved for epilepsy — larger confirmatory trials needed
VNS vs. RNS vs. DBS — Comparison Table
| Feature | VNS | RNS (NeuroPace) | ANT-DBS |
|---|---|---|---|
| Mechanism | Open-loop ± autostim | Closed-loop (ECoG-responsive) | Open-loop (scheduled cycling) |
| Target | Left vagus nerve (peripheral) | Seizure focus (intracranial) | Anterior thalamus (intracranial) |
| Best indication | Broad: focal + generalized; not surgical candidate | 1–2 foci; eloquent cortex; bilateral MTLE | Diffuse/multifocal; failed other options |
| Efficacy at 3+ yr | ~50% reduction (stable) | 82% median reduction (3 yr PAS) | 69% reduction (5 yr SANTE) |
| Seizure freedom | 2–8% | 42% (≥6 mo, PAS) | 18% experienced ≥6-month seizure-free intervals at some point during 5-year follow-up (SANTE; cumulative, not point-prevalence) |
| Diagnostic value | None | Yes — chronic ambulatory ECoG | None (LFP research only) |
| Key side effects | Hoarseness 62%, cough, OSA | Infection 3.7%, lead revision 4.7% | Depression 15%, memory 13% |
| Intracranial surgery | No | Yes (craniotomy) | Yes (stereotactic) |
| Reversible | Yes | Yes | Yes |
| MRI compatibility | Conditional (model-dependent) | Conditional (specific protocols) | Conditional (specific SAR limits) |
| Device-specific MRI footnote: VNS — 1.5T conditional with restrictions on body imaging (newer models expanded). RNS — 1.5T head-only conditional with specific transmit/receive coil; body MRI contraindicated. ANT-DBS — Medtronic systems 1.5T (newer Percept/Activa 3T full-body under specific conditions). | |||
| FDA approval | 1997 | 2013 | 2018 |
| Relative cost | Lowest | Highest | Moderate |
When to Choose Which — Decision Framework
VNS — Choose When:
- Not a surgical candidate (non-localizable, generalized, or declined intracranial surgery)
- Generalized epilepsy or LGS (broadest indication among the three)
- First-line neuromodulation — simplest, lowest invasiveness, most established
- Pediatric patients (≥4 years FDA-approved)
RNS — Choose When:
- Identifiable focus in eloquent cortex (resection would cause deficit)
- Bilateral MTLE — treatment + diagnostic clarification of dominant focus
- Want chronic ECoG diagnostic data to guide future surgery
- 1–2 localizable foci with failed or declined resection
DBS — Choose When:
- Multifocal or diffuse onset within focal epilepsy networks
- Failed VNS after 2+ years of optimized therapy
- Generalized epilepsy: CMN-DBS for LGS (when available)
- Temporal lobe epilepsy not amenable to resection or RNS
Key Principles
- VNS is generally first-line neuromodulation due to lowest invasiveness
- Escalate to intracranial neuromodulation if VNS fails after optimized therapy
- VNS can remain active even if intracranial device is added
- None of these devices precludes future resective surgery
Board Pearls & Clinical Pearls
💎 Board Pearl
- Left vagus nerve for VNS: Chosen because the right vagus provides more sinoatrial node innervation — right-sided stimulation carries higher arrhythmia risk
- VNS most common side effect = hoarseness (62%): Occurs only during ON phase; improves with time; mitigate by reducing current or lowering frequency to 20 Hz
- RNS is the only device with diagnostic capability: Chronic ambulatory ECoG can lateralize seizures in bilateral MTLE and guide subsequent curative resection
- ANT-DBS and the circuit of Papez: Depression (15%) and memory complaints (13%) are expected given the ANT’s position in the hippocampus–fornix–mammillary body–anterior thalamus–cingulate circuit
- All three devices show progressive improvement: Efficacy increases over 1–5 years — do not declare neuromodulation failure before 2 years of optimized therapy
- Pivotal trial sham comparisons: VNS E03/E05: high vs. low stim; RNS: 38% vs. 17%; DBS SANTE: 40% vs. 15% — all achieved statistical significance
Clinical Pearl
VNS autostimulation detects ictal tachycardia (present in 80–90% of seizures) and delivers an extra stimulation burst. Exercise and anxiety can trigger false detections. The heart rate threshold must be individualized (typically 20–40% above resting) to balance sensitivity and false-positive rate.
Clinical Pearl
RNS as a diagnostic-therapeutic bridge in bilateral MTLE: Chronic ECoG may reveal that ≥90% of seizures arise from one hippocampus, enabling curative mesial temporal resection. The device can remain in place post-resection to monitor and treat contralateral seizures.
References
- Friedman D, Engel J. Surgical treatments, devices, and nonmedical management of epilepsy. Continuum (Minneap Minn) 2025;31(1):165–186.
- Ryvlin P, Rheims S, Hirsch LJ, Sokolov A, Jehi L. Neuromodulation in epilepsy: state-of-the-art approved therapies. Lancet Neurol 2021;20(12):1038–1047.
- Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg 2011;115(6):1248–1255.
- Morrell MJ; RNS System in Epilepsy Study Group. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. Neurology 2011;77(13):1295–1304.
- Nair DR, Laxer KD, Weber PB, et al. Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. Neurology 2020;95(9):e1244–e1256.
- NeuroPace. Data from the Long-Term Post-Approval Study of the RNS System in Focal Epilepsy. Presented at 2025 AAN Annual Meeting. April 2025.
- Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia 2010;51(5):899–908.
- Salanova V, Witt T, Worth R, et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology 2015;84(10):1017–1025.
- Salanova V, Sperling MR, Gross RE, et al. The SANTE study at 10 years of follow-up: effectiveness, safety, and sudden unexpected death in epilepsy. Epilepsia 2021;62(6):1306–1317.
- Peltola J, Colon AJ, Pimentel J, et al. Deep brain stimulation of the anterior nucleus of the thalamus in drug-resistant epilepsy in the MORE multicenter patient registry. Neurology 2023;100(18):e1852–e1865.
- Dalic LJ, Warren AEL, Bulluss KJ, et al. DBS of thalamic centromedian nucleus for Lennox-Gastaut syndrome (ESTEL trial). Ann Neurol 2022;91(2):253–267.
- Fisher RS, Velasco AL. Electrical brain stimulation for epilepsy. Nat Rev Neurol 2014;10(5):261–270.
Continue reading — sign in
The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.